These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
599 related items for PubMed ID: 10191222
21. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L. Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282 [Abstract] [Full Text] [Related]
22. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H. Paediatr Drugs; 2007 Jan; 9 Suppl 1():21-31. PubMed ID: 17536872 [Abstract] [Full Text] [Related]
23. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Parkins MD, Elborn JS. Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231 [Abstract] [Full Text] [Related]
26. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa. Lapointe JR, Bourget C, Mainville S, Lafleur L, Lagacé J, Montplaisir S. J Chemother; 1989 Jul; 1(4 Suppl):184-6. PubMed ID: 16312360 [No Abstract] [Full Text] [Related]
29. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Tré-Hardy M, Macé C, El Manssouri N, Vanderbist F, Traore H, Devleeschouwer MJ. Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647 [Abstract] [Full Text] [Related]
30. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500 [Abstract] [Full Text] [Related]
32. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. Ratjen F, Brockhaus F, Angyalosi G. J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887 [Abstract] [Full Text] [Related]
33. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. Woodward TC, Brown R, Sacco P, Zhang J. J Med Econ; 2010 Dec; 13(3):492-9. PubMed ID: 20670159 [Abstract] [Full Text] [Related]
39. Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation. Prescrire Int; 2002 Dec; 11(62):177-8. PubMed ID: 12469696 [Abstract] [Full Text] [Related]
40. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Konstan MW, Flume PA, Galeva I, Wan R, Debonnett LM, Maykut RJ, Angyalosi G. Pediatr Pulmonol; 2016 Apr; 51(4):372-8. PubMed ID: 26709158 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]